|Day Low/High||302.73 / 321.49|
|52 Wk Low/High||291.10 / 442.00|
Shares of Regeneron Pharmaceuticals were lower Monday after The Food and Drug Administration put a drug study on hold.
On days like this, the money just keeps sloshing around.
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.
That may be the best way to get through the notorious month of August.
Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says Jim Cramer.
Biotech, restaurants and retail have been left for dead but are showing signs of life today.
Stocks like Facebook or Palo Alto Networks are expensive for the moment.
With Pfizer deal dead, Allergan is ready to go shopping.
The biopharmaceutical company's chart is still pointed lower.
TheStreet’s Jim Cramer discussed the bear market in biotechs while answering viewer questions from social media on Friday.
U.S. stocks gave up earlier gains as the energy sector continued to sell off despite relatively stable crude prices on Tuesday.
The biopharmaceutical company is in for a deeper bear phase.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.
5 biotech stocks that could outperform the overall market in 2016.
TheStreet looked at stocks that soared under the Federal Reserve’s QE program, and Jim Cramer explains why some shares performed better than others.
TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.
Stocks are trading in a relatively narrow range, but are slightly down after Federal Reserve chair Janet Yellen hinted at a possible December rate hike. Still, her remarks are only having a minor impact on the market given the many Fed "head fakes" ...